Agio Pharmaceuticals Limited — Guaifenesin Exporter Profile
Indian Pharmaceutical Exporter · #5 for Guaifenesin · $781.2K export value · DGFT Verified
Agio Pharmaceuticals Limited is the #5 Indian exporter of Guaifenesin with $781.2K in export value and 34 verified shipments. Agio Pharmaceuticals Limited holds a 2.9% market share in Guaifenesin exports across 3 countries. The company exports 15 pharmaceutical products worth $11.9M across 8 therapeutic categories.
Agio Pharmaceuticals Limited — Guaifenesin Export Profile: Buyers & Destinations
Where Does Agio Pharmaceuticals Limited Export Guaifenesin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| RUSSIA | $828.8K | 34 | 96.9% |
| KYRGYZSTAN | $16.9K | 1 | 2.0% |
| UZBEKISTAN | $9.5K | 1 | 1.1% |
Agio Pharmaceuticals Limited exports Guaifenesin to 3 countries. The largest destination is RUSSIA accounting for 96.9% of Agio Pharmaceuticals Limited's Guaifenesin shipments, followed by KYRGYZSTAN (2.0%) and UZBEKISTAN (1.1%). These destinations reflect Agio Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Guaifenesin from Agio Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| AGIO RUS LLC | RUSSIA | $824.8K | 33 |
| NEMAN-FARM LLC | KYRGYZSTAN | $16.9K | 1 |
| AGIO HEALTHCARE INTERNATIONAL LLC | UZBEKISTAN | $9.5K | 1 |
| OOO E T C PHARMA | RUSSIA | $3.9K | 1 |
Agio Pharmaceuticals Limited supplies Guaifenesin to 4 buyers globally. The largest buyer is AGIO RUS LLC (RUSSIA), followed by NEMAN-FARM LLC (KYRGYZSTAN) and AGIO HEALTHCARE INTERNATIONAL LLC (UZBEKISTAN). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Guaifenesin Export Value and How Much Does Agio Pharmaceuticals Limited Contribute?
India exported $19.9M worth of Guaifenesin through 1,050 shipments from 151 suppliers to 77 countries, serving 278 buyers globally. Agio Pharmaceuticals Limited contributes $781.2K to this total, accounting for 2.9% of India's Guaifenesin exports. Agio Pharmaceuticals Limited ships Guaifenesin to 3 countries through 4 buyers.
What Is the Average Shipment Value for Agio Pharmaceuticals Limited's Guaifenesin Exports?
Agio Pharmaceuticals Limited's average Guaifenesin shipment value is $23.0K per consignment, based on 34 shipments totaling $781.2K. The largest destination is RUSSIA (96.9% of Agio Pharmaceuticals Limited's Guaifenesin exports).
How Does Agio Pharmaceuticals Limited Compare to Other Indian Guaifenesin Exporters?
Agio Pharmaceuticals Limited ranks #5 among 151 Indian Guaifenesin exporters with a 2.9% market share. The top 3 exporters are GRANULES INDIA LIMITED ($9.1M), ELYSIUM PHARMACEUTICALS LTD ($3.9M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($899.7K). Agio Pharmaceuticals Limited processed 34 shipments to 3 destination countries.
What Guaifenesin Formulations Does Agio Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| KOFASMA SYRUP 200 ML (BROMHEXINE + GUAIFENESIN + SALBUTAMOL SYRUP) | $546.4K | 23 |
| KOFASMA SYRUP 200 ML BROMHEXINE + GUAIFENESIN + SALBUTAMOL SYRUP | $135.8K | 4 |
| KOFASMA SYRUP 100 ML (BROMHEXINE + GUAIFENESIN + SALBUTAMOL SYRUP) | $59.6K | 4 |
| KOFASMA SYRUP 100 ML SALBUTAMOL + BROMOHEXINE + GUAIFENESIN SYRUP | $48.7K | 1 |
| KOFASMA SYRUP 100 ML (SALBUTAMOL + BROMOHEXINE + GUAIFENESIN SYRUP) | $34.3K | 1 |
| KOFASMA SYRUP (SALBUTAMOL, BROMHEXINE HYDROCHLORIDE & GUAIFENESIN SYRUP (2MG+4MG+100MG)) | $16.9K | 1 |
| KOFASMA SYRUP (SALBUTAMOL + BROMHEXINE+GUAIFENESIN+MENTHOL SYRUP) | $9.5K | 1 |
| KOFASMA SYRUP 200 ML SALBUTAMOL BROMOHEXINE GUAIFENESIN SYRUP SALBUTAMOL SULPHATE EQ TO SALBUTAMOL BP 2 0MG | $3.9K | 1 |
Agio Pharmaceuticals Limited exports 8 distinct Guaifenesin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is KOFASMA SYRUP 200 ML (BROMHEXINE + GUAIFENESIN + SALBUTAMOL with 23 shipments worth $546.4K.
How Does Agio Pharmaceuticals Limited Compare to Nearest Guaifenesin Exporters?
Exporters ranked immediately above and below #5 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $899.7K | 31 | 1 | $29.0K |
| 4 | BRAWN LABORATORIES LIMITED | $793.2K | 24 | 2 | $33.1K |
| 5 | AGIO PHARMACEUTICALS LIMITED ★ | $781.2K | 34 | 3 | $23.0K |
| 7 | EMCURE PHARMACEUTICALS LIMITED | $645.9K | 46 | 11 | $14.0K |
| 8 | GLENMARK PHARMACEUTICALS LIMITED | $594.8K | 30 | 7 | $19.8K |
Agio Pharmaceuticals Limited ranks #5 among 151 Indian Guaifenesin exporters. Average shipment value of $23.0K compared to the market average of $131.8K. The closest competitors by value are SUN PHARMACEUTICAL INDUSTRIES LIMITED and BRAWN LABORATORIES LIMITED.
Which Indian Ports Ship Guaifenesin Exports?
| Port | Shipments | % Share |
|---|---|---|
| HYDERABAD ICD | 118 | 11.2% |
| NHAVA SHEVA SEA (INNSA1) | 94 | 9.0% |
| JNPT | 74 | 7.0% |
| JNPT/ NHAVA SHEVA SEA | 70 | 6.7% |
| HYDERABAD AIR | 53 | 5.0% |
| HYDERABAD ICD (INSNF6) | 50 | 4.8% |
| MUNDRA SEA (INMUN1) | 50 | 4.8% |
| MUNDRA SEA | 47 | 4.5% |
What Other Respiratory & OTC Products Does Agio Pharmaceuticals Limited Export?
Agio Pharmaceuticals Limited also exports these respiratory & otc products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Agio Pharmaceuticals Limited's Guaifenesin Exports
Recent geopolitical developments have introduced complexities into the pharmaceutical export landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, causing increased freight charges and potential losses for Indian exporters. According to Pharmaceutical Commerce, maritime carriers' booking suspensions and diversions around the Cape of Good Hope are elongating lead times and pressurizing Suez-linked lanes, disproportionately impacting time-sensitive pharmaceutical replenishment cycles. This situation poses challenges for Agio Pharmaceuticals, particularly in maintaining timely deliveries to key markets.
In the United States, recent tariff implementations have affected a significant portion of Indian exports. The Federation of Indian Export Organisations highlighted that the latest U.S. tariffs impact nearly 55% of India's outbound shipments to America, placing Indian exporters at a competitive disadvantage. For Agio, which relies on the U.S. market, these tariffs could necessitate strategic adjustments to pricing and supply chain logistics.
The European Union's stringent regulatory changes, including the Falsified Medicines Directive, demand enhanced compliance measures from exporters. Agio's ability to adapt to these evolving standards will be crucial in sustaining its market presence in the EU.
Agio Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
The global pharmaceutical industry is witnessing heightened regulatory scrutiny, with agencies like the U.S. FDA increasing inspections of manufacturing facilities. India, hosting over 600 US FDA-approved sites, faces challenges in maintaining compliance. The US FDA conducted more than 200 inspections in 2023, with plans to increase this number in 2024. For Agio Pharmaceuticals, ensuring adherence to Good Manufacturing Practices (GMP) and other quality standards is imperative to avoid potential export bans or reputational damage.
Additionally, the prevalence of counterfeit drugs has raised concerns about India's reputation as a reliable supplier. Agio must implement robust quality control systems and transparent governance to navigate this landscape effectively.
About Agio Pharmaceuticals Limited
Agio Pharmaceuticals Limited exports 15 products worth $11.9M. Beyond Guaifenesin, top products include Dexamethasone, Phenylephrine, Clotrimazole, Prednisolone, Salbutamol. View the complete Agio Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Guaifenesin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Guaifenesin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Agio Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 36 individual customs records matching Agio Pharmaceuticals Limited exporting Guaifenesin, covering 8 formulations to 3 countries via 4 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 77+ countries, 278+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Guaifenesin Export Data from Agio Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Agio Pharmaceuticals Limited's Guaifenesin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Agio Pharmaceuticals Limited
Full Company Profile →
15 products · $11.9M total trade · 8 categories
Guaifenesin Stats
Company Overview
Top Products by Agio Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Agio Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Guaifenesin. For current shipment-level data, contact TransData Nexus.